865156-55-4

Basic information

• Product Name: 4-broMo-2-(3-Methoxypropoxy)pyridine
• Synonyms: 4-broMo-2-(3-Methoxypropoxy)pyridine
• CAS NO: 865156-55-4
• Molecular Formula: C₉H₁₂BrNO₂
• Molecular Weight: 246.10108
• Mol File: 865156-55-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-broMo-2-(3-Methoxypropoxy)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-(3-Methoxypropoxy)pyridine(865156-55-4)
• EPA Substance Registry System: 4-broMo-2-(3-Methoxypropoxy)pyridine(865156-55-4)

Safety Data

• Hazardous Substances Data: 865156-55-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Bromo-2-(3-methoxypropoxy)pyridine serves as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows it to be a versatile building block for the development of new medications.
Used in Agrochemical Production:
4-broMo-2-(3-Methoxypropoxy)pyridine also finds application in the production of agrochemicals, contributing to the development of pesticides and other agricultural products that help ensure crop protection and yield enhancement.
Used in Antimicrobial Research:
4-Bromo-2-(3-methoxypropoxy)pyridine has been studied for its potential antimicrobial properties, indicating its possible use in the development of new antibiotics or antimicrobial agents to combat resistant bacteria.
Used in Antifungal Applications:
Additionally, research into its antifungal properties suggests that 4-broMo-2-(3-Methoxypropoxy)pyridine could be utilized in creating antifungal medications, addressing the needs of treating fungal infections effectively.

Upstream product

• 36953-37-4 4-bromo-2(1H)-pyridinone 
• 61542-10-7 1-iodo-3-methoxypropane 

Relevant articles and documents

5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION

The application relatés to novel alkanamides of the general formula (I) where X is -CH2- or >CH-OH; (A) R1 is e.g. an optionally substituted heterocyclyl radical or an optionally substituted polycyclic, unsaturated hydrocarbon radical where X is hydroxymethylene; R2 is C1-C6-alkyl or C3-C6-cydoalkyl; R3 are each independently H, C1-C6-alkyl, C1-6-alkoxycarbonyl or C1-C6-alkanoyl; R4 is C1-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl or unsubstituted or substituted aryl-C1-C6-alkyl; R5 is Cl-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkanoyloxy- C1-C6-alkyl, C1-C6-aminoalkyl, C1-C6-alkylamino-C1-C6-alkyl, C1-C6-dialkylamino-Cl-C6-alkyl, C1-C6-alkanoylamido-C1-C6-alkyl, HO(O)C-C1-C6-alkyl, C1-C6-alkyl-O-(O)C-C1-C6-alkyl, H2N-C(O)-C1-C6-alkyl, C1-C6-alkyl-HN-C(O)-C1-C6-alkyl, (C1,-C6-alkyl)2N-C(O)-C1-C6-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, cyano-C1-C6-alkyl, halo-Cl-C6-alkyl, optionally substituted aryl--Co-C6-alkyl, optionally substituted C3-C8-cycloalkyl-Co-C6-alkyl or optionally substituted heterocydyl-Co-C6-alkyl; to a process for their preparation and to the use of these compounds as medicines, especially as renin inhibitors for the treatment of hypertension.

ORGANIC COMPOUNDS

The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.